Avanir Shares Rise on Zenvia Trial Data
Avanir, a pharmaceutical company developing treatments for CNS disorders and inflammatory diseases, announced that its multiple sclerosis drug Zenvia met its goal in a six-month clinical trial.
8036
Opexa Shares Soar on Multiple Sclerosis Trial Data
Opexa Therapeutics announced that 83 percent of clinical trial patients taking its therapeutic vaccine Tovaxin remained relapse-free for a year.